nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CYP1A1—polycystic ovary syndrome	0.516	1	CbGaD
Haloperidol—CYP2C19—urine—polycystic ovary syndrome	0.00512	0.04	CbGeAlD
Haloperidol—EBP—uterus—polycystic ovary syndrome	0.00496	0.0387	CbGeAlD
Haloperidol—CYP1A2—urine—polycystic ovary syndrome	0.00419	0.0327	CbGeAlD
Haloperidol—CYP2C9—urine—polycystic ovary syndrome	0.00397	0.031	CbGeAlD
Haloperidol—EBP—endocrine gland—polycystic ovary syndrome	0.00378	0.0295	CbGeAlD
Haloperidol—Hypothermia—Metformin—polycystic ovary syndrome	0.00368	0.0845	CcSEcCtD
Haloperidol—Body temperature decreased—Metformin—polycystic ovary syndrome	0.00368	0.0845	CcSEcCtD
Haloperidol—HTR2A—urine—polycystic ovary syndrome	0.00327	0.0255	CbGeAlD
Haloperidol—CYP3A4—urine—polycystic ovary syndrome	0.00303	0.0237	CbGeAlD
Haloperidol—CYP2D6—urine—polycystic ovary syndrome	0.00298	0.0233	CbGeAlD
Haloperidol—Sertindole—ADRA1D—polycystic ovary syndrome	0.00279	0.251	CrCbGaD
Haloperidol—CBR1—adrenal cortex—polycystic ovary syndrome	0.00275	0.0215	CbGeAlD
Haloperidol—H1F0—embryo—polycystic ovary syndrome	0.00275	0.0215	CbGeAlD
Haloperidol—Droperidol—ADRA1A—polycystic ovary syndrome	0.00249	0.224	CrCbGaD
Haloperidol—CBR1—endometrium—polycystic ovary syndrome	0.00246	0.0192	CbGeAlD
Haloperidol—Sertindole—ADRA1B—polycystic ovary syndrome	0.00238	0.214	CrCbGaD
Haloperidol—GRIN2B—endocrine gland—polycystic ovary syndrome	0.00232	0.0181	CbGeAlD
Haloperidol—UGT1A9—endocrine gland—polycystic ovary syndrome	0.00229	0.0179	CbGeAlD
Haloperidol—CBR1—uterus—polycystic ovary syndrome	0.00226	0.0177	CbGeAlD
Haloperidol—H1F0—adrenal cortex—polycystic ovary syndrome	0.00225	0.0176	CbGeAlD
Haloperidol—CBR1—pituitary gland—polycystic ovary syndrome	0.00222	0.0173	CbGeAlD
Haloperidol—CBR1—adipose tissue—polycystic ovary syndrome	0.00221	0.0173	CbGeAlD
Haloperidol—H1F0—endometrium—polycystic ovary syndrome	0.00201	0.0157	CbGeAlD
Haloperidol—CBR1—adrenal gland—polycystic ovary syndrome	0.00198	0.0155	CbGeAlD
Haloperidol—CYP3A7—endocrine gland—polycystic ovary syndrome	0.0019	0.0148	CbGeAlD
Haloperidol—Loperamide—POMC—polycystic ovary syndrome	0.00186	0.167	CrCbGaD
Haloperidol—H1F0—uterus—polycystic ovary syndrome	0.00185	0.0145	CbGeAlD
Haloperidol—CBR1—female gonad—polycystic ovary syndrome	0.00185	0.0144	CbGeAlD
Haloperidol—CBR1—vagina—polycystic ovary syndrome	0.00184	0.0144	CbGeAlD
Haloperidol—H1F0—pituitary gland—polycystic ovary syndrome	0.00182	0.0142	CbGeAlD
Haloperidol—H1F0—adipose tissue—polycystic ovary syndrome	0.00181	0.0142	CbGeAlD
Haloperidol—CBR1—endocrine gland—polycystic ovary syndrome	0.00172	0.0134	CbGeAlD
Haloperidol—SIGMAR1—adrenal cortex—polycystic ovary syndrome	0.00163	0.0127	CbGeAlD
Haloperidol—H1F0—adrenal gland—polycystic ovary syndrome	0.00163	0.0127	CbGeAlD
Haloperidol—HTR2B—adrenal cortex—polycystic ovary syndrome	0.00162	0.0127	CbGeAlD
Haloperidol—Sertindole—ADRA1A—polycystic ovary syndrome	0.00161	0.144	CrCbGaD
Haloperidol—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00154	0.0353	CcSEcCtD
Haloperidol—Lethargy—Metformin—polycystic ovary syndrome	0.00153	0.0351	CcSEcCtD
Haloperidol—H1F0—female gonad—polycystic ovary syndrome	0.00152	0.0118	CbGeAlD
Haloperidol—H1F0—vagina—polycystic ovary syndrome	0.00151	0.0118	CbGeAlD
Haloperidol—SIGMAR1—endometrium—polycystic ovary syndrome	0.00145	0.0113	CbGeAlD
Haloperidol—HTR2B—endometrium—polycystic ovary syndrome	0.00145	0.0113	CbGeAlD
Haloperidol—H1F0—endocrine gland—polycystic ovary syndrome	0.00141	0.011	CbGeAlD
Haloperidol—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00138	0.0318	CcSEcCtD
Haloperidol—Breast disorder—Metformin—polycystic ovary syndrome	0.00135	0.0311	CcSEcCtD
Haloperidol—SIGMAR1—uterus—polycystic ovary syndrome	0.00134	0.0105	CbGeAlD
Haloperidol—HTR2B—uterus—polycystic ovary syndrome	0.00134	0.0104	CbGeAlD
Haloperidol—SIGMAR1—pituitary gland—polycystic ovary syndrome	0.00131	0.0103	CbGeAlD
Haloperidol—SIGMAR1—adipose tissue—polycystic ovary syndrome	0.00131	0.0102	CbGeAlD
Haloperidol—HTR2B—adipose tissue—polycystic ovary syndrome	0.00131	0.0102	CbGeAlD
Haloperidol—Sweating increased—Metformin—polycystic ovary syndrome	0.00126	0.029	CcSEcCtD
Haloperidol—Neutropenia—Metformin—polycystic ovary syndrome	0.00121	0.0278	CcSEcCtD
Haloperidol—SIGMAR1—adrenal gland—polycystic ovary syndrome	0.00117	0.00917	CbGeAlD
Haloperidol—HTR2B—adrenal gland—polycystic ovary syndrome	0.00117	0.00915	CbGeAlD
Haloperidol—KCNH2—endometrium—polycystic ovary syndrome	0.00116	0.00903	CbGeAlD
Haloperidol—Drowsiness—Metformin—polycystic ovary syndrome	0.00116	0.0265	CcSEcCtD
Haloperidol—HTR1B—endocrine gland—polycystic ovary syndrome	0.00113	0.00881	CbGeAlD
Haloperidol—SIGMAR1—female gonad—polycystic ovary syndrome	0.0011	0.00855	CbGeAlD
Haloperidol—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00109	0.0251	CcSEcCtD
Haloperidol—SIGMAR1—vagina—polycystic ovary syndrome	0.00109	0.0085	CbGeAlD
Haloperidol—HTR2B—vagina—polycystic ovary syndrome	0.00109	0.00848	CbGeAlD
Haloperidol—KCNH2—uterus—polycystic ovary syndrome	0.00107	0.00832	CbGeAlD
Haloperidol—DRD2—pituitary gland—polycystic ovary syndrome	0.00106	0.00829	CbGeAlD
Haloperidol—HTR2A—embryo—polycystic ovary syndrome	0.00106	0.00826	CbGeAlD
Haloperidol—KCNH2—pituitary gland—polycystic ovary syndrome	0.00105	0.00817	CbGeAlD
Haloperidol—Hepatitis—Metformin—polycystic ovary syndrome	0.00104	0.0238	CcSEcCtD
Haloperidol—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00102	0.0234	CcSEcCtD
Haloperidol—Eye disorder—Metformin—polycystic ovary syndrome	0.000969	0.0222	CcSEcCtD
Haloperidol—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000963	0.0221	CcSEcCtD
Haloperidol—Angiopathy—Metformin—polycystic ovary syndrome	0.000941	0.0216	CcSEcCtD
Haloperidol—Immune system disorder—Metformin—polycystic ovary syndrome	0.000937	0.0215	CcSEcCtD
Haloperidol—KCNH2—adrenal gland—polycystic ovary syndrome	0.000935	0.0073	CbGeAlD
Haloperidol—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000935	0.0214	CcSEcCtD
Haloperidol—HRH1—endometrium—polycystic ovary syndrome	0.000927	0.00724	CbGeAlD
Haloperidol—CYP2C19—vagina—polycystic ovary syndrome	0.000908	0.00709	CbGeAlD
Haloperidol—Malnutrition—Metformin—polycystic ovary syndrome	0.000903	0.0207	CcSEcCtD
Haloperidol—CYP1A1—uterus—polycystic ovary syndrome	0.0009	0.00703	CbGeAlD
Haloperidol—CYP1A1—adipose tissue—polycystic ovary syndrome	0.00088	0.00687	CbGeAlD
Haloperidol—KCNH2—female gonad—polycystic ovary syndrome	0.000872	0.0068	CbGeAlD
Haloperidol—Muscle spasms—Metformin—polycystic ovary syndrome	0.000868	0.0199	CcSEcCtD
Haloperidol—KCNH2—vagina—polycystic ovary syndrome	0.000866	0.00676	CbGeAlD
Haloperidol—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000861	0.00672	CbGeAlD
Haloperidol—Vision blurred—Metformin—polycystic ovary syndrome	0.000851	0.0195	CcSEcCtD
Haloperidol—CYP2C19—endocrine gland—polycystic ovary syndrome	0.00085	0.00663	CbGeAlD
Haloperidol—Tremor—Metformin—polycystic ovary syndrome	0.000846	0.0194	CcSEcCtD
Haloperidol—HRH1—adipose tissue—polycystic ovary syndrome	0.000835	0.00652	CbGeAlD
Haloperidol—DRD2—endocrine gland—polycystic ovary syndrome	0.000823	0.00642	CbGeAlD
Haloperidol—KCNH2—endocrine gland—polycystic ovary syndrome	0.000811	0.00633	CbGeAlD
Haloperidol—Hypertension—Metformin—polycystic ovary syndrome	0.00078	0.0179	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000763	0.0175	CcSEcCtD
Haloperidol—HRH1—adrenal gland—polycystic ovary syndrome	0.000749	0.00585	CbGeAlD
Haloperidol—Oedema—Metformin—polycystic ovary syndrome	0.000737	0.0169	CcSEcCtD
Haloperidol—CYP1A1—female gonad—polycystic ovary syndrome	0.000736	0.00575	CbGeAlD
Haloperidol—CYP1A1—vagina—polycystic ovary syndrome	0.000732	0.00571	CbGeAlD
Haloperidol—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000723	0.0166	CcSEcCtD
Haloperidol—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000722	0.0166	CcSEcCtD
Haloperidol—CYP3A5—female gonad—polycystic ovary syndrome	0.00072	0.00562	CbGeAlD
Haloperidol—Skin disorder—Metformin—polycystic ovary syndrome	0.000716	0.0164	CcSEcCtD
Haloperidol—CYP3A5—vagina—polycystic ovary syndrome	0.000715	0.00559	CbGeAlD
Haloperidol—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000712	0.0163	CcSEcCtD
Haloperidol—Anorexia—Metformin—polycystic ovary syndrome	0.000702	0.0161	CcSEcCtD
Haloperidol—HTR2A—pituitary gland—polycystic ovary syndrome	0.000701	0.00547	CbGeAlD
Haloperidol—HRH1—female gonad—polycystic ovary syndrome	0.000699	0.00545	CbGeAlD
Haloperidol—HRH1—vagina—polycystic ovary syndrome	0.000694	0.00542	CbGeAlD
Haloperidol—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000694	0.00542	CbGeAlD
Haloperidol—ABCB1—embryo—polycystic ovary syndrome	0.000693	0.00541	CbGeAlD
Haloperidol—Hypotension—Metformin—polycystic ovary syndrome	0.000689	0.0158	CcSEcCtD
Haloperidol—CYP1A1—endocrine gland—polycystic ovary syndrome	0.000685	0.00534	CbGeAlD
Haloperidol—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000669	0.00523	CbGeAlD
Haloperidol—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000659	0.00514	CbGeAlD
Haloperidol—Dyspnoea—Metformin—polycystic ovary syndrome	0.000657	0.0151	CcSEcCtD
Haloperidol—Somnolence—Metformin—polycystic ovary syndrome	0.000655	0.015	CcSEcCtD
Haloperidol—HRH1—endocrine gland—polycystic ovary syndrome	0.00065	0.00507	CbGeAlD
Haloperidol—Dyspepsia—Metformin—polycystic ovary syndrome	0.000649	0.0149	CcSEcCtD
Haloperidol—Decreased appetite—Metformin—polycystic ovary syndrome	0.000641	0.0147	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000636	0.0146	CcSEcCtD
Haloperidol—Constipation—Metformin—polycystic ovary syndrome	0.00063	0.0145	CcSEcCtD
Haloperidol—HTR2A—adrenal gland—polycystic ovary syndrome	0.000626	0.00489	CbGeAlD
Haloperidol—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000607	0.0139	CcSEcCtD
Haloperidol—Urticaria—Metformin—polycystic ovary syndrome	0.000585	0.0134	CcSEcCtD
Haloperidol—HTR2A—vagina—polycystic ovary syndrome	0.00058	0.00453	CbGeAlD
Haloperidol—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000568	0.00444	CbGeAlD
Haloperidol—HTR2A—endocrine gland—polycystic ovary syndrome	0.000543	0.00424	CbGeAlD
Haloperidol—CYP2D6—female gonad—polycystic ovary syndrome	0.000532	0.00415	CbGeAlD
Haloperidol—Pruritus—Metformin—polycystic ovary syndrome	0.000521	0.012	CcSEcCtD
Haloperidol—ABCB1—endometrium—polycystic ovary syndrome	0.000507	0.00396	CbGeAlD
Haloperidol—Diarrhoea—Metformin—polycystic ovary syndrome	0.000504	0.0116	CcSEcCtD
Haloperidol—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000502	0.00392	CbGeAlD
Haloperidol—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000494	0.00386	CbGeAlD
Haloperidol—Dizziness—Metformin—polycystic ovary syndrome	0.000487	0.0112	CcSEcCtD
Haloperidol—Vomiting—Metformin—polycystic ovary syndrome	0.000469	0.0108	CcSEcCtD
Haloperidol—ABCB1—uterus—polycystic ovary syndrome	0.000467	0.00365	CbGeAlD
Haloperidol—Rash—Metformin—polycystic ovary syndrome	0.000465	0.0107	CcSEcCtD
Haloperidol—Dermatitis—Metformin—polycystic ovary syndrome	0.000464	0.0107	CcSEcCtD
Haloperidol—Headache—Metformin—polycystic ovary syndrome	0.000462	0.0106	CcSEcCtD
Haloperidol—ABCB1—pituitary gland—polycystic ovary syndrome	0.000459	0.00358	CbGeAlD
Haloperidol—ABCB1—adipose tissue—polycystic ovary syndrome	0.000457	0.00357	CbGeAlD
Haloperidol—Nausea—Metformin—polycystic ovary syndrome	0.000438	0.01	CcSEcCtD
Haloperidol—ABCB1—adrenal gland—polycystic ovary syndrome	0.00041	0.0032	CbGeAlD
Haloperidol—ABCB1—female gonad—polycystic ovary syndrome	0.000382	0.00299	CbGeAlD
Haloperidol—ABCB1—vagina—polycystic ovary syndrome	0.00038	0.00297	CbGeAlD
Haloperidol—ABCB1—endocrine gland—polycystic ovary syndrome	0.000356	0.00278	CbGeAlD
Haloperidol—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	1.29e-05	4.27e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.28e-05	4.26e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	1.28e-05	4.25e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	1.28e-05	4.25e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	1.27e-05	4.23e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—LEP—polycystic ovary syndrome	1.27e-05	4.22e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	1.27e-05	4.22e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NGFR—polycystic ovary syndrome	1.27e-05	4.2e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.27e-05	4.2e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—MTHFR—polycystic ovary syndrome	1.26e-05	4.18e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	1.26e-05	4.18e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	1.26e-05	4.17e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—POMC—polycystic ovary syndrome	1.26e-05	4.17e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PRL—polycystic ovary syndrome	1.25e-05	4.16e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—TH—polycystic ovary syndrome	1.25e-05	4.16e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.25e-05	4.13e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	1.24e-05	4.13e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NGFR—polycystic ovary syndrome	1.24e-05	4.12e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IRS2—polycystic ovary syndrome	1.24e-05	4.12e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.24e-05	4.11e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	1.24e-05	4.1e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—POMC—polycystic ovary syndrome	1.24e-05	4.1e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PRL—polycystic ovary syndrome	1.23e-05	4.1e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PRL—polycystic ovary syndrome	1.23e-05	4.09e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	1.23e-05	4.06e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—SLC2A4—polycystic ovary syndrome	1.22e-05	4.04e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	1.22e-05	4.04e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PPARG—polycystic ovary syndrome	1.22e-05	4.03e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—LEP—polycystic ovary syndrome	1.22e-05	4.03e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	1.21e-05	4.03e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.21e-05	4.01e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	1.2e-05	3.99e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—POMC—polycystic ovary syndrome	1.2e-05	3.98e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—INS—polycystic ovary syndrome	1.19e-05	3.96e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.19e-05	3.95e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.19e-05	3.95e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	1.19e-05	3.94e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.19e-05	3.94e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	1.19e-05	3.93e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IRS1—polycystic ovary syndrome	1.18e-05	3.91e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	1.18e-05	3.91e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	1.18e-05	3.9e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	1.17e-05	3.89e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.17e-05	3.89e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.17e-05	3.89e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.17e-05	3.88e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.17e-05	3.88e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	1.16e-05	3.86e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	1.16e-05	3.84e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IRS2—polycystic ovary syndrome	1.16e-05	3.83e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.15e-05	3.83e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IRS1—polycystic ovary syndrome	1.15e-05	3.83e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CYP19A1—polycystic ovary syndrome	1.15e-05	3.8e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—LEP—polycystic ovary syndrome	1.15e-05	3.8e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	1.14e-05	3.79e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IRS1—polycystic ovary syndrome	1.14e-05	3.77e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—POMC—polycystic ovary syndrome	1.13e-05	3.77e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—LEP—polycystic ovary syndrome	1.13e-05	3.75e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—INS—polycystic ovary syndrome	1.13e-05	3.74e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	1.12e-05	3.72e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—POMC—polycystic ovary syndrome	1.11e-05	3.69e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.11e-05	3.67e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—INS—polycystic ovary syndrome	1.1e-05	3.67e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	1.1e-05	3.66e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	1.1e-05	3.64e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—POMC—polycystic ovary syndrome	1.09e-05	3.63e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IGF1—polycystic ovary syndrome	1.09e-05	3.62e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKT2—polycystic ovary syndrome	1.09e-05	3.62e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1.09e-05	3.62e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	1.09e-05	3.61e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—INS—polycystic ovary syndrome	1.09e-05	3.61e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	1.09e-05	3.6e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.09e-05	3.6e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IRS1—polycystic ovary syndrome	1.08e-05	3.6e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—GNAS—polycystic ovary syndrome	1.08e-05	3.6e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	1.08e-05	3.59e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	1.08e-05	3.59e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.07e-05	3.55e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.07e-05	3.54e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IGF1—polycystic ovary syndrome	1.05e-05	3.49e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.05e-05	3.49e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKT2—polycystic ovary syndrome	1.05e-05	3.49e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	1.05e-05	3.47e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—POMC—polycystic ovary syndrome	1.04e-05	3.46e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—INS—polycystic ovary syndrome	1.04e-05	3.44e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.04e-05	3.44e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.03e-05	3.43e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.03e-05	3.43e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.03e-05	3.42e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	1.03e-05	3.42e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—TH—polycystic ovary syndrome	1.03e-05	3.4e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—GNAS—polycystic ovary syndrome	1.02e-05	3.39e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PPARG—polycystic ovary syndrome	1.02e-05	3.39e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.02e-05	3.39e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.02e-05	3.37e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.01e-05	3.37e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.01e-05	3.36e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—POMC—polycystic ovary syndrome	1.01e-05	3.35e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.01e-05	3.35e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	1.01e-05	3.34e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IGF1—polycystic ovary syndrome	1e-05	3.33e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKT2—polycystic ovary syndrome	1e-05	3.33e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—INS—polycystic ovary syndrome	1e-05	3.33e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—TH—polycystic ovary syndrome	1e-05	3.32e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1e-05	3.32e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.99e-06	3.31e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	9.98e-06	3.31e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	9.93e-06	3.3e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	9.93e-06	3.3e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	9.86e-06	3.27e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—POMC—polycystic ovary syndrome	9.84e-06	3.27e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—INS—polycystic ovary syndrome	9.79e-06	3.25e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	9.78e-06	3.24e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—NCOR1—polycystic ovary syndrome	9.75e-06	3.23e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	9.74e-06	3.23e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—POMC—polycystic ovary syndrome	9.71e-06	3.22e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	9.71e-06	3.22e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—INS—polycystic ovary syndrome	9.66e-06	3.2e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.53e-06	3.16e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IGF1—polycystic ovary syndrome	9.47e-06	3.14e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKT2—polycystic ovary syndrome	9.46e-06	3.14e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—TH—polycystic ovary syndrome	9.43e-06	3.13e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	9.4e-06	3.12e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	9.38e-06	3.11e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	9.38e-06	3.11e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—TH—polycystic ovary syndrome	9.35e-06	3.1e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IGF1—polycystic ovary syndrome	9.34e-06	3.1e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKT2—polycystic ovary syndrome	9.34e-06	3.1e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	9.23e-06	3.06e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	9.18e-06	3.04e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	9.15e-06	3.04e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	9.12e-06	3.02e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	9.1e-06	3.02e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.99e-06	2.98e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.87e-06	2.94e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	8.84e-06	2.93e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	8.7e-06	2.89e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	8.68e-06	2.88e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	8.65e-06	2.87e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	8.65e-06	2.87e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	8.63e-06	2.86e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—MTHFR—polycystic ovary syndrome	8.61e-06	2.86e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	8.55e-06	2.84e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	8.51e-06	2.82e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	8.49e-06	2.82e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	8.38e-06	2.78e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	8.37e-06	2.78e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—IL6—polycystic ovary syndrome	8.35e-06	2.77e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	8.17e-06	2.71e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	8.17e-06	2.71e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	8.08e-06	2.68e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—IL6—polycystic ovary syndrome	8.04e-06	2.67e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—TH—polycystic ovary syndrome	7.99e-06	2.65e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	7.97e-06	2.65e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	7.78e-06	2.58e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	7.77e-06	2.58e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	7.76e-06	2.58e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	7.72e-06	2.56e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	7.7e-06	2.55e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	7.68e-06	2.55e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	7.67e-06	2.54e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	7.63e-06	2.53e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	7.59e-06	2.52e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	7.58e-06	2.51e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	7.56e-06	2.51e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	7.43e-06	2.47e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	7.39e-06	2.45e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	7.39e-06	2.45e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	7.38e-06	2.45e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	7.33e-06	2.43e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	7.31e-06	2.43e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	7.31e-06	2.42e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	7.3e-06	2.42e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	7.29e-06	2.42e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	7.27e-06	2.41e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	7.27e-06	2.41e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	7.26e-06	2.41e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—INS—polycystic ovary syndrome	7.25e-06	2.41e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	7.24e-06	2.4e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	7.24e-06	2.4e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	7.15e-06	2.37e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—IL6—polycystic ovary syndrome	7.14e-06	2.37e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	7.14e-06	2.37e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.13e-06	2.37e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	7.13e-06	2.36e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	7.05e-06	2.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	7.03e-06	2.33e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	7.03e-06	2.33e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	7.02e-06	2.33e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	7.01e-06	2.33e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PPARG—polycystic ovary syndrome	6.98e-06	2.32e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.98e-06	2.32e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	6.95e-06	2.31e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	6.89e-06	2.29e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—POMC—polycystic ovary syndrome	6.89e-06	2.29e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	6.88e-06	2.28e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.87e-06	2.28e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—INS—polycystic ovary syndrome	6.85e-06	2.27e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.79e-06	2.25e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.68e-06	2.22e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.67e-06	2.21e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.56e-06	2.18e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	6.52e-06	2.16e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	6.48e-06	2.15e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	6.43e-06	2.13e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	6.21e-06	2.06e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.18e-06	2.05e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TH—polycystic ovary syndrome	6.17e-06	2.05e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.1e-06	2.02e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	6e-06	1.99e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	5.89e-06	1.95e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	5.72e-06	1.9e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	5.64e-06	1.87e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	5.64e-06	1.87e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—INS—polycystic ovary syndrome	5.61e-06	1.86e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	5.58e-06	1.85e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—POMC—polycystic ovary syndrome	5.5e-06	1.83e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	5.49e-06	1.82e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—INS—polycystic ovary syndrome	5.47e-06	1.82e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	5.47e-06	1.81e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	5.38e-06	1.78e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	5.37e-06	1.78e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	5.26e-06	1.74e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	5.21e-06	1.73e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	5.18e-06	1.72e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—INS—polycystic ovary syndrome	5.16e-06	1.71e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	5.14e-06	1.71e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—INS—polycystic ovary syndrome	5.11e-06	1.7e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	5.03e-06	1.67e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—polycystic ovary syndrome	4.93e-06	1.64e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	4.83e-06	1.6e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	4.8e-06	1.59e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—polycystic ovary syndrome	4.75e-06	1.58e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.67e-06	1.55e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.59e-06	1.52e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.58e-06	1.52e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	4.55e-06	1.51e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	4.54e-06	1.5e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	4.45e-06	1.48e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	4.39e-06	1.46e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—INS—polycystic ovary syndrome	4.37e-06	1.45e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—polycystic ovary syndrome	4.28e-06	1.42e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	4.24e-06	1.41e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—polycystic ovary syndrome	4.22e-06	1.4e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	3.44e-06	1.14e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	3.39e-06	1.12e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—INS—polycystic ovary syndrome	3.37e-06	1.12e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	3.23e-06	1.07e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	3.18e-06	1.05e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	3.17e-06	1.05e-05	CbGpPWpGaD
